PDCD1 and lung adenocarcinoma: Similarly, immunotherapy for several solid cancers including lung adenocarcinoma with immune checkpoint inhibitors (nivolumab or pembrolizumab) exhibiting improved PD‐1 inhibitor efficacy showed high baseline fecal concentrations of SCFAs mainly propionic, butyric, valeric and acetic acid with longer progression‐free survival (Nomura et al, 2020).